From Terminal to Chronic: 7-Year Follow-Up Data from the CROWN Study
This review examines 7-year CROWN trial data showing lorlatinib’s unprecedented durability in ALK-positive NSCLC, highlighting survival gains, CNS protection, resistance suppression, and toxicity management.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.